ARAF and small cell lung carcinoma: While there are no available large datasets to determine the prevalence of ARAF amplification in SCLC-transformed tumors following EGFR-TKI treatment, we interrogated the prevalence of ARAF amplification in a large clinical sequencing cohort including 293 SCLC samples, identifying ARAF amplification in 1 of 9 cases of SCLC with EGFR-activating mutations, compared to only 1 of 284 cases of EGFR wildtype SCLC (p = 0.06 by Fisher’s test) [16].